CD4 and neoplasm: In this study we showed that inhibiting naive CD4+ T cell recruitment by knocking down PITPNM3 in tumor-bearing humanized mice could reduce TI Tregs, restore immune killing of tumors and suppress tumor growth and metastases, confirming the role of PITNM3 recognition of CCL18 in TI Treg biogenesis.